Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03113487 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03113487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03113487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 1, 2018
Completion date
April 8, 2027
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent platinum-resistant fallopian tube carcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent platinum-resistant primary peritoneal carcinoma